AstraZeneca Stock Tops 3 Cash Flow Bargains Worth A Closer Look

Energy driven inflation remains a live question for central banks, which keeps investors guessing about interest rate paths and future cash flows. When markets are this focused on policy signals, solid cash generation that is priced cheaply can be overlooked. That is where the Undervalued Stocks Based On Cash Flows screener comes in. This article highlights three stocks from the screener that stand out on valuation and cash flow potential.

The stocks covered below are just a starting sample, and the full screen surfaced 46 more companies with similarly compelling cash flow and valuation stories that are not included here. To identify and analyze the ideas that best fit your own approach, head straight to the Undervalued Stocks Based On Cash Flows screener.

AstraZeneca (LSE:AZN)

AstraZeneca is a large biopharmaceutical company that discovers, develops, manufactures and sells prescription medicines across oncology, cardiovascular and metabolic diseases, respiratory and immunology, vaccines and rare diseases. It currently reports all of its roughly $61.4b in revenue from pharmaceuticals. The stock has a substantial size in the market with a value of about £177.7b.

For investors looking at cash flow backed value, AstraZeneca offers a mix of a deep oncology and rare disease pipeline, high return on equity and analyst expectations that earnings and revenue growth will outpace the wider UK market. At the same time, the company carries a high debt load and depends heavily on a handful of blockbuster drugs that face future pricing pressure, patent cliffs and regulatory risks. Recent positive trial results across drugs such as Enhertu and camizestrant, plus multiple late stage approvals, are among the reasons why many investors view AstraZeneca as a high quality compounder that the market may not be fully pricing, especially when weighing the strength of its pipeline against these risks.

AstraZeneca’s cash rich pipeline and market size often draw attention, yet the full picture of its earnings power and drug concentration risk is not always obvious. Get the clearer story in the 4 key rewards and 2 important warning signs

Build your own cash flow shortlist

AstraZeneca and the two other stocks in this list all surfaced from a single Simply Wall St screener, but the real edge comes when you build your own filters. Use our flexible Screener to blend valuation, cash flows, balance sheet strength and risks to suit your style, or start with one of our curated Investing Ideas.

Coats Group (LSE:COA)

Coats Group is a long established supplier of threads, structural components and software for apparel and footwear brands worldwide, with operations across apparel and footwear divisions. It generates around $772.6 million in revenue from Apparel and $567.6 million from Footwear, supported by a segment adjustment of $256.2 million, and has a market value of about £1.6 billion.

Coats Group gives you exposure to premium and more sustainable materials in footwear and apparel, including OrthoLite’s foam insole technology and growing recycled thread sales, within a cash flow focused story that screens as materially undervalued on Simply Wall St’s model. Analysts expect solid revenue and earnings growth over the next few years, helped by cost savings from factory consolidation and broader cross selling to over 800 footwear brands. At the same time, the company still carries high debt, an unstable dividend record and a relatively new board. If you want to see how those positives and risks stack up for long term returns, the detailed cash flow and risk breakdown is worth a closer look.

Coats Group’s cash flow profile appears materially undervalued, while its premium and recycled materials continue to expand their presence in global footwear and apparel markets. Get the full context in the analysis report for Coats Group

Foresight Group Holdings (LSE:FSG)

Foresight Group Holdings is an investment manager focused on real assets and private equity, backing infrastructure, renewable energy and smaller growth companies across the UK and several European markets, as well as Australia. It generates about £114.8 million from Real Assets and £50.1 million from Private Equity, with most revenue tied to managing funds and earning fees on those mandates. The stock has a market value of roughly £556 million.

Foresight Group Holdings sits at the intersection of growing demand for renewable and infrastructure assets and a still modest market share in its core regions. This gives room for assets under management to scale if fundraising continues to gain traction. The company combines high current profitability, with a net margin near 28% and strong return on equity, with ongoing share buybacks that steadily shrink the share count. The flip side is reliance on external borrowing and performance fees, along with heavy exposure to UK and European policy on green energy and private funds, which can put pressure on earnings when conditions shift. Investors who want to see how that balance of growth potential and funding and regulatory risk plays out in the numbers will find there is more to Foresight than the headline metrics suggest.

Foresight Group Holdings’ high net margin and fee driven model hint at earnings power that the market may not fully appreciate. See how that story looks across assets under management, buybacks and policy risk in the analysis report for Foresight Group Holdings

Seeking Fresh Alternatives Before Crowds?

New ideas can move quickly when momentum builds and fresh stories start circulating. Consider reviewing potential opportunities before prices move significantly. Scan these under the radar for now ideas and decide what belongs on your watchlist.

• Identify fast-moving upstarts that may still be early in their journey by checking the curated 51 elite penny stocks with strong financials while it is still attracting limited attention.
• Track companies involved in the AI build out and see which ones may be contributing to that trend with the focused 56 AI infrastructure stocks today.
• Build a watchlist of income-focused ideas using the hand picked 7 dividend fortresses before yields change or more investors focus on the same stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com